Trial Profile
A Single-Dose Study to Investigate the Pharmacokinetics of MK0859 in Subjects With Impaired Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Anacetrapib (Primary)
- Indications Atherosclerosis
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 30 Apr 2014 Results published in the Journal of Clinical Pharmacology.
- 07 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned end date changed from 1 Jul 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.